With sales ris­ing and ef­fi­ca­cy ques­tions swirling, Gilead faces calls to re­lin­quish lu­cra­tive pri­or­i­ty re­view vouch­er

Thir­teen years ago, Con­gress en­act­ed an at­tempt­ed so­lu­tion to a long-run­ning phar­ma prob­lem. Al­though in­fec­tious dis­eases that af­flict­ed the de­vel­op­ing world or could trig­ger pan­demics …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.